Could a nasal spray after childbirth ward off postpartum depression?

NCT ID NCT07639099

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether a nasal spray containing esketamine and dexmedetomidine, given twice after childbirth, can lower the chance of postpartum depression in women who already had mild depressive symptoms during pregnancy. Esketamine is a fast-acting antidepressant, and dexmedetomidine may reduce its side effects while also helping mood. The trial will follow 164 women for 42 days after birth to see if the spray reduces depressive symptoms compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
esketamine and dexmedetomidine nasal spray
What this could lead to
If it works, this could offer a fast-acting, non-invasive option to prevent postpartum depression in at-risk women.
What could go wrong
This is a Phase 4 trial with only 164 participants, so results may not apply to everyone. Esketamine can cause side effects like dizziness or hallucinations, and the combination's safety in new mothers is still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEPRESSIVE SYMPTOMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100034, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.